-
J.
Douglas,
K.
Margolin
(2002)
The treatment of brain metastases from malignant melanoma.
Seminars in oncology, 29 5
-
C.
Leonetti,
A.
Biroccio,
A.
Candiloro,
G.
Citro,
C.
Fornari,
Marcella
Mottolese,
D.
Bufalo,
Gabriella
Zupi
(1999)
Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research, 5 9
-
C.
Powers,
S.
Mcleskey,
A.
Wellstein
(2000)
Fibroblast growth factors, their receptors and signaling.
Endocrine-related cancer, 7 3
-
G.
Pratesi,
G.
Beretta,
F.
Zunino
(2004)
Gimatecan, a novel camptothecin with a promising preclinical profile
Anti-Cancer Drugs, 15
-
D.
Laccabue,
M.
Tortoreto,
S.
Veneroni,
P.
Perego,
E.
Scanziani,
M.
Zucchetti,
M.
Zaffaroni,
M.
D’Incalci,
E.
Bombardelli,
F.
Zunino,
G.
Pratesi
(2001)
A novel taxane active against an orthotopically growing human glioma xenograft
Cancer, 92
-
Gloria
Lee,
S.
Dallas,
M.
Hong,
R.
Bendayan
(2001)
Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations.
Pharmacological reviews, 53 4
-
C.
Turner,
S.
Gururangan,
J.
Eastwood,
K.
Bottom,
M.
Watral,
Rodney
Beason,
R.
McLendon,
A.
Friedman,
S.
Tourt-Uhlig,
L.
Miller,
H.
Friedman
(2002)
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Neuro-oncology, 4
-
G.
Pratesi,
C.
Manzotti,
M.
Tortoreto,
R.
Audisio,
Franco
Zunino
(1991)
Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.
British Journal of Cancer, 63
-
(2003)
A phase I study of the oral camptothecin gimatecan with a design of concerted dose escalation in three schedules of different dosing-duration
-
G.
Pratesi,
M.
Cesare,
N.
Carenini,
P.
Perego,
S.
Righetti,
C.
Cucco,
L.
Merlini,
C.
Pisano,
S.
Penco,
P.
Carminati,
L.
Vesci,
F.
Zunino
(2002)
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8 12
-
I.
Fidler
(2002)
Critical determinants of metastasis.
Seminars in cancer biology, 12 2
-
R.
Chasty,
Liu-Yin
J
(1993)
Acute tumour lysis syndrome.
British journal of hospital medicine, 49 7
-
B.
Giovanella,
J.
Stehlin,
M.
Wall,
M.
Wani,
A.
Nicholas,
Leroy
Liu,
R.
Silber,
M.
Potměšil
(1989)
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.
Science, 246 4933
-
M.
Brower,
D.
Carney,
H.
Oie,
A.
Gazdar,
J.
Minna
(1986)
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Cancer research, 46 2
-
M.
Nicoletto,
R.
Padrini,
M.
Palumbo,
A.
Ziade,
R.
Ragazzi,
G.
Pratesi,
G.
Artioli,
M.
Cesare,
F.
Zunino
(2002)
Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.
Oncology reports, 9 6
-
Chris
Takimoto,
John
Wright,
S.
Arbuck
(1998)
Clinical applications of the camptothecins.
Biochimica et biophysica acta, 1400 1-3
-
A.
Croce,
G.
Bottiroli,
R.
Supino,
E.
Favini,
V.
Zuco,
F.
Zunino
(2004)
Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Biochemical pharmacology, 67 6
-
(2000)
Fibroblast growth factors, their receptors and signalling
-
Paola
Perego,
M.
Cesare,
P.
Isabella,
N.
Carenini,
G.
Beggiolin,
Gabriella
Pezzoni,
Manlio
Palumbo,
Loris
Tartaglia,
G.
Pratesi,
Claudio
Pisano,
Paolo
Carminati,
G.
Scheffer,
Franco
Zunino
(2001)
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Cancer research, 61 16
-
(1920)
7364 Gimatecan in Ortothopic and Metastatic Tumor Xenografts Research
-
(2002)
Clinical pharmacokinetic profile of gimatecan (ST1481), a new oral camptothecin derivative
-
(2002)
Current status and perspective in the development of camptothecins
-
H.
Friedman,
P.
Houghton,
S.
Schold,
S.
Keir,
D.
Bigner
(2004)
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
Cancer Chemotherapy and Pharmacology, 34
-
M.
Cesare,
G.
Pratesi,
Paola
Perego,
N.
Carenini,
S.
Tinelli,
Lucio
Merlini,
S.
Penco,
Claudio
Pisano,
Federica
Bucci,
L.
Vesci,
Silvia
Pace,
F.
Capocasa,
Paolo
Carminati,
Franco
Zunino
(2001)
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
Cancer research, 61 19
-
F.
Zunino,
G.
Pratesi
(2004)
Camptothecins in clinical development
Expert Opinion on Investigational Drugs, 13
-
G.
Petrangolini,
G.
Pratesi,
M.
Cesare,
R.
Supino,
C.
Pisano,
M.
Marcellini,
V.
Giordano,
D.
Laccabue,
C.
Lanzi,
F.
Zunino
(2003)
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Molecular cancer research : MCR, 1 12
-
C.
Verschraegen,
K.
Jaeckle,
B.
Giovanella,
V.
Knight,
B.
Gilbert
(2000)
Alternative Administration of Camptothecin Analogues
Annals of the New York Academy of Sciences, 922
-
S.
Dallavalle,
A.
Ferrari,
B.
Biasotti,
L.
Merlini,
S.
Penco,
G.
Gallo,
M.
Marzi,
M.
Tinti,
R.
Martinelli,
C.
Pisano,
P.
Carminati,
N.
Carenini,
G.
Beretta,
P.
Perego,
M.
Cesare,
G.
Pratesi,
F.
Zunino
(2001)
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.
Journal of medicinal chemistry, 44 20
-
Leroy
Liu
(1989)
DNA topoisomerase poisons as antitumor drugs.
Annual review of biochemistry, 58
-
Jean
Bã©nard,
Jacqueline
Silva,
Marie‐Christine
Blois,
Pierre
Boyer,
P.
Duvillard,
E.
Chiric,
G.
Riou
(1985)
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Cancer research, 45 10
-
H.
Hochster,
S.
Wadler,
C.
Runowicz,
L.
Liebes,
H.
Cohen,
R.
Wallach,
J.
Sorich,
B.
Taubes,
J.
Speyer
(1999)
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 8
-
B.
Behrens,
T.
Hamilton,
H.
Masuda,
K.
Grotzinger,
J.
Whang‐Peng,
K.
Louie,
T.
Knutsen,
W.
Mckoy,
R.
Young,
R.
Ozols
(1987)
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Cancer research, 47 2
-
H.
Friedman,
T.
Kerby,
S.
Fields,
Janice
Zilisch,
D.
Graden,
R.
McLendon,
P.
Houghton,
S.
Arbuck,
I.
Cokgor,
A.
Friedman
(1999)
Topotecan treatment of adults with primary malignant glioma
Cancer, 85
-
(2003)
Phase I/II trial of gimatecan in patients with recurrent malignant glioma
-
Thomas
Burke,
Z.
Mi
(1994)
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
Journal of medicinal chemistry, 37 1
-
M.
Schirner
(2004)
Antiangiogenic Chemotherapeutic Agents
Cancer and Metastasis Reviews, 19
-
F.
Zunino,
Sabrina
Dallavalleb,
Diletta
Laccabuea,
Giovanni
Berettaa,
Lucio
Merlinib,
G.
Pratesi
(2002)
Current status and perspectives in the development of camptothecins.
Current pharmaceutical design, 8 27
-
C.
Hare,
Gertrude
Elion,
peter
Houghton,
J.
Houghton,
S.
Keir,
S.
Marcelli,
D.
Bigner,
H.
Friedman
(1996)
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
Cancer Chemotherapy and Pharmacology, 39
-
(2003)
Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors